Recaticimab

Recaticimab is a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein involved in cholesterol regulation. According to the study titled "Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering" (PMID: 42274993), Recaticimab has been engineered to bind with high affinity to PCSK9, preventing it from interacting with low-density lipoprotein receptors (LDLR) on liver cells. This interaction is crucial because PCSK9 normally promotes the degradation of LDLR, which are responsible for clearing LDL cholesterol from the bloodstream.

By inhibiting PCSK9, Recaticimab increases the number of LDL receptors available on the surface of liver cells, thereby enhancing the clearance of LDL cholesterol and leading to lower blood cholesterol levels. Furthermore, the Fc-engineering of Recaticimab is designed to prolong its half-life and enhance its duration of action, ensuring a more sustained lipid-lowering effect compared to other monoclonal antibodies targeting PCSK9.

The Phase 1b/2 study detailed in "Impact of PCSK9 Inhibitor Recaticimab on Hyperlipidemia and Plasma Glucose" (PMID: 41196105) supports these findings by showing a significant reduction in LDL cholesterol in patients with hyperlipidemia. The systematic reviews and meta-analyses (e.g., PMID: 41801769 and 41585950) further confirm Recaticimab's efficacy in reducing cholesterol levels in patients with dyslipidemia and hypercholesterolemia.

Disclaimer: This information is for educational purposes and not a substitute for professional medical advice. Always consult a healthcare provider for medical issues.

Recaticimab is used primarily for managing hypercholesterolemia and dyslipidemia. It is an Fc-engineered PCSK9 monoclonal antibody designed to provide a more prolonged lipid-lowering effect. Clinical applications of Recaticimab include:

1. Hypercholesterolemia: Recaticimab has shown efficacy in reducing LDL cholesterol levels in patients with hypercholesterolemia. A Phase 3 study (REMAIN-3) demonstrated its effectiveness in adult patients with heterozygous familial hypercholesterolemia, significantly lowering LDL cholesterol compared to placebo.

2. Dyslipidemia: Systematic reviews and meta-analyses confirm Recaticimab’s safety and efficacy in managing dyslipidemia, highlighting its favorable impact on lipid profiles and its long-lasting effects.

3. Acute Coronary Syndrome: Ongoing trials explore its impact on acute coronary syndrome (ACS), specifically assessing early intensive lipid-lowering therapy's effect on patient prognosis.

4. Potential in Atherosclerosis: While not yet recruiting, trials are planned to evaluate Recaticimab's role in treating intracranial atherosclerosis-related acute ischemic stroke and symptomatic stenosis, indicating potential broader cardiovascular applications.

5. Plasma Glucose Impact: Early-phase studies also suggest a potential impact on plasma glucose, although further research is needed.

In summary, Recaticimab is primarily used for lipid management in hypercholesterolemia and dyslipidemia, with ongoing research exploring broader cardiovascular benefits. Clinical trials continue to investigate its effectiveness in various contexts, including ACS and atherosclerosis.

Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice. Always consult healthcare professionals for medical concerns.

Recaticimab Safety Profile

Known Side Effects:
Recaticimab, as a PCSK9 monoclonal antibody, has been generally well-tolerated in clinical trials. Common side effects reported include mild injection site reactions, such as redness, swelling, or discomfort. Additionally, some patients have experienced headache and nasopharyngitis. While these effects are typically mild and self-limiting, monitoring is recommended.

Contraindications:
There is limited direct evidence regarding specific contraindications for recaticimab. As with other monoclonal antibodies, it is contraindicated in patients with known hypersensitivity to the drug or its components.

Drug Interactions:
Current evidence does not highlight any significant drug interactions specific to recaticimab. However, as with any new therapeutic agent, caution should be exercised when it is used in combination with other lipid-lowering therapies until further studies are conducted.

Populations to Avoid Use:

• Pregnant and Nursing Women: There is insufficient data on the effects of recaticimab during pregnancy or lactation. Use is not recommended unless the potential benefits justify the potential risk to the fetus or infant.
• Pediatrics: Safety and efficacy in pediatric populations have not been established, warranting caution.
• Severe Hepatic Impairment: While not specifically contraindicated, individuals with significant liver dysfunction should use recaticimab with caution due to the pharmacological mechanisms of PCSK9 inhibitors.

Overall, while the evidence covers some safety aspects of recaticimab, further post-marketing surveillance and studies are needed to establish a comprehensive safety profile, especially for long-term use and in varied patient demographics.

Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Recaticimab is a novel monoclonal antibody engineered to enhance lipid-lowering effects by targeting PCSK9, an enzyme that influences cholesterol levels.

A 2025 study published in Biomedical and Environmental Sciences evaluated the impact of Recaticimab on hyperlipidemia and plasma glucose in a randomized, double-blind, placebo-controlled Phase 1b/2 trial. The study indicated that Recaticimab effectively reduces LDL cholesterol levels with a favorable safety profile.

In the Phase 3 REMAIN-3 trial, detailed in Cardiovascular Research (2025), Recaticimab was assessed in patients with heterozygous familial hypercholesterolemia. This multicenter, double-blind, placebo-controlled study demonstrated significant LDL cholesterol reduction over the trial period.

A systematic review and meta-analysis published in Pharmacotherapy (2026) evaluated multiple randomized controlled trials to assess Recaticimab's efficacy and safety. The analysis highlighted its consistent cholesterol-lowering effects and manageable side effects.

Further, a network meta-analysis in Cardiovascular Therapeutics explored four PCSK9 monoclonal antibodies, including Recaticimab, reaffirming its efficacy in reducing cholesterol levels.

Population pharmacokinetics and dynamics modeling, reported in Clinical Pharmacokinetics (2025), suggested predictable behavior of Recaticimab in both healthy volunteers and hypercholesterolemia patients, supporting its clinical use.

Overall, Recaticimab shows promising potential in treating hypercholesterolemia, backed by multiple trials confirming its safety and efficacy. However, evidence is still emerging, and further long-term studies are warranted to fully establish its clinical benefits.

Disclaimer: This information is for educational purposes only and not a substitute for professional medical advice.

Recaticimab is an Fc-engineered monoclonal antibody targeting PCSK9, designed for long-lasting lipid-lowering effects. The dosing protocols reported in the literature involve:

1. Initial Dosing: Typically administered as a subcutaneous injection. Studies suggest an initial dose of Recaticimab followed by maintenance doses at regular intervals.

2. Maintenance Doses: Commonly administered every 2 to 4 weeks depending on individual patient response and tolerance. Some studies propose a monthly dosing regimen due to its long-lasting effects.

3. Administration Considerations: Doses are adjusted based on the patient's cholesterol levels and response to therapy. Health care providers might adjust dosing frequency to achieve the desired LDL cholesterol reduction.

These protocols are derived from various studies and clinical trial data, notably for use in managing hypercholesterolemia and dyslipidemia. It is important to consult healthcare professionals for personalized medical advice and before making any decisions based on these protocols.

Disclaimer: This information is intended for educational purposes only and is not a substitute for professional medical advice. Always consult a healthcare provider for medical decisions tailored to individual health needs.

Outcomes Summary for Recaticimab

Recaticimab, a PCSK9 monoclonal antibody, has shown promise in managing lipid levels according to recent studies. Here’s a summary of its reported outcomes:

1. Lipid Reduction:

   • The publication titled "Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering" (PMID: 42274993) reveals that Recaticimab significantly lowers LDL cholesterol levels, suggesting a durable effect in lipid reduction. This aligns with a systematic review in "Pharmacotherapy" (PMID: 41801769), confirming its efficacy in lowering lipid levels in dyslipidemia patients.

2. Familial Hypercholesterolemia:

   • The REMAIN-3 study (PMID: 40911402) shows Recaticimab effectively reduces cholesterol in adults with heterozygous familial hypercholesterolemia. This Phase 3 trial noted significant LDL-C reduction compared to placebo.

3. Hyperlipidemia:

   • A Phase 1b/2 study (PMID: 41196105) demonstrated Recaticimab’s ability to manage hyperlipidemia with observed reductions in lipid metrics. The study further looked at the impact on plasma glucose, although definitive glucose-related outcomes were not detailed.

4. Safety and Efficacy:

   • The systematic review and meta-analysis in "Cardiovascular therapeutics" (PMID: 41585950) consolidate data on the efficacy and safety, supporting the use of Recaticimab in lowering cholesterol levels with a favorable safety profile.

5. Pharmacokinetics and Pharmacodynamics:

   • The "Clinical pharmacokinetics" study (PMID: 40587053) outlines the pharmacokinetic properties, supporting its long-lasting lipid-lowering effects and potential administration benefits.

The evidence, primarily from systematic reviews and controlled trials, suggests Recaticimab is effective in lipid reduction, particularly in familial and general hypercholesterolemia, with a good safety profile. Ongoing and future trials may further clarify its broader impacts.

Disclaimer: This summary is for informational purposes only and should not be considered medical advice. For personal health decisions, please consult a healthcare professional.